Successful treatment of resistant Fusarium solani keratitis with liposomal amphotericin B;Efficacité de l'amphotéricine B liposomale dans le traitement d'une kératite Fusarium solani résistante

Journal Francais d'Ophtalmologie

Volumn 32, Issue 10, 2009, Pages 721-726

  Touvron, G ^a   Denis, D ^a   Doat, M ^b   Girard, A ^b   Brandely, M L ^b   Chast, F ^b   Renard, G ^b  

^a HÔPITAL NORD   (France)

^b HÔTEL DIEU   (France)

Author keywords

Amphotericin B; Fusarium; Keratiis; Liposomal amphotericin B; Voriconazole

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; LIPOSOME;

ANTIFUNGAL RESISTANCE; ARTICLE; CASE REPORT; FUNGAL EYE INFECTION; FUSARIUM; HUMAN; KERATITIS; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOSIS; REMISSION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG RESISTANCE, FUNGAL; EYE INFECTIONS, FUNGAL; FUSARIUM; HUMANS; KERATITIS; LIPOSOMES; MALE; MIDDLE AGED; MYCOSES; REMISSION INDUCTION;

EID: 77949655799     PISSN: 01815512     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jfo.2009.10.011     Document Type: Article

References (40)

1. Chowdhary A, Singh K. Spectrum of fungal keratitis in North India. Cornea 2005;24:8-15.
2. Bharathi MJ, Ramakrishnan R, Vasu S, Meenakshi R, Palaniappan R. Epidemiological characteristics and laboratory diagnosis of fungal keratitis. A three-year study. Indian J Ophthalmol 2003;51:315-321
3. Wong TY, Ng TP, Fong KS, Tan DT. Risk factors and clinical outcomes between fungal and bacterial keratitis: a comparative study. CLAO J 1997;23:275-281
4. Centre for Health Protection. Update on cases of fungal corneal infections. Press release, 16th may 2006.
5. Donnio A, Van Nuoi DN, Catanese M, Desbois N, Ayeboua L, Merle H. Outbreak of keratomycosis attributable to Fusarium solani in the French West Indies. Am J Ophthalmol 2007;143:356-358
6. Khor WB, Aung T, Saw SM, Wong TY, Tambyah PA, Tan AL, et al. An outbreak of Fusarium keratitis associated with contact lens wear in Singapore. JAMA 2006;295:2867-2873
7. Centers For Disease Control and Prevention, C.f.D.C.a.P. Update: Fusarium keratitis-United States, 2005-2006. MMWR Morb Mortal Wkly Rep, 2006; 55: p. 563-564
8. Chang DC, Grant GB, O'Donnell K, Wannemuehler KA, Noble- Wang J, Rao CY, et al. Fusarium Keratitis Investigation Team. Multistate outbreak of Fusarium keratitis associated with use of a contact lens solution. JAMA 2006;296:953-963
9. Kaufmann C, Frueh BE, Messerli J, Bernauer W, Thiel MA. Contact lens-associated fusarium keratitis in Switzerland. Klin Monatsbl Augenheilkd 2008;225:418-421
10. Gaujoux T, Chatel MA, Chaumeil C, Laroche L, Borderie V. Outbreak of contact lens-related Fusarium keratitis in France. Cornea 2008;27:1018-1021
11. Zhang S, Ahearn DG, Noble-Wang JA, Stulting RD, Schwam BL, Simmons RB, et al. Growth and survival of Fusarium solani-F. oxysporum complex on stressed multipurpose contact lens care solution films on plastic surfaces in situ and in vitro. Cornea 2006;25:1210-1216
12. Xie L, Dong X, Shi W. Treatment of fungal keratitis by penetrating keratoplasty. Br J Ophthalmol 2001;85:1070-1074
13. Xie L, Zhai H, Shi W. Penetrating keratoplasty for corneal perforations in fungal keratitis. Cornea 2007;26:158-162
14. Alfonso EC, Cantu-Dibildox J, Munir WM, Miller D, O'Brien TP, Karp CL, et al. Insurgence of Fusarium keratitis associated with contact lens wear. Arch Ophthalmol 2006;124:941-947
15. Reuben A, Anaissie E, Nelson PE, Hashem R, Legrand C, Ho DH, et al. Antifungal susceptibility of 44 clinical isolates of Fusarium species determined by using a broth microdilution method. Antimicrob Agents Chemother 1989;33:1647-1649
16. Kalavathy CM, Parmar P, Kaliamurthy J, Philip VR, Ramalingam MD, Jesudasan CA, et al. Comparison of topical itraconazole 1 % with topical natamycin 5 % for the treatment of filamentous fungal keratitis. Cornea 2005;24:449-452
17. Dursun D, Fernandez V, Miller D, Alfonso EC. Advanced fusarium keratitis progressing to endophthalmitis. Cornea 2003;22:300-303
18. Gianoli F, Guex-Crosier Y, Marchetti O, Wolfensberger TJ, Spahn B. Nécrose du segment antérieur sur kératomycose à Fusarium polyrésistant: à propos d'un cas. J Fr Ophtalmol 2005;28:498-501.
19. Guarro J, Rubio C, Gene J, Cano J, Gil J, Benito R, Moranderia MJ, Miguez E. Case of keratitis caused by an uncommon Fusarium species. J Clin Microbiol 2003;41:5823-5826
20. Espinel-Ingroff A. In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. J Clin Microbiol 1998;36:198-202.
21. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother 1998;42:741-745
22. Klont RR, Eggink CA, Rijs AJ,Wesseling P, Verweij PE. Successful treatment of Fusarium keratitis with cornea transplantation and topical and systemic voriconazole. Clin Infect Dis 2005;40:e110-2.
23. Thiel MA, Zinkernagel AS, Burhenne J, Kaufmann C, Haefeli WE. Voriconazole concentration in human aqueous humor and plasma during topical or combined topical and systemic administration for fungal keratitis. Antimicrob Agents Chemother 2007;51:239-244
24. Vorwerk CK, Streit F, Binder L, Tuchen S, Knop C, Behrens- Baumann W. Aqueous humor concentration of voriconazole after topical administration in rabbits. Graefes Arch Clin Exp Ophthalmol 2008;246:1179-1183
25. Bunya VY, Hammersmith KM, Rapuano CJ, Ayres BD, Cohen EJ. Topical and oral voriconazole in the treatment of fungal keratitis. Am J Ophthalmol 2007;143:151-153
26. Durand ML, Kim IK, D'Amico DJ, Loewenstein JI, Tobin EH, Kieval SJ, et al. Successful treatment of Fusarium endophthalmitis with voriconazole and Aspergillus endophthalmitis with voriconazole plus caspofungin. Am J Ophthalmol 2005;140:552-554
27. Polizzi A, Siniscalchi C, Mastromarino A, Sacca SC. Effect of voriconazole on a corneal abscess caused by fusarium. Acta Ophthalmol Scand 2004;82:762-764
28. Giaconi JA, Marangon FB, Miller D, Alfonso EC. Voriconazole and fungal keratitis: a report of two treatment failures. J Ocul Pharmacol Ther 2006;22:437-439
29. Tu EY, McCartney DL, Beatty RF, Springer KL, Levy J, Edward D. Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592). Am J Ophthalmol 2007;143: 222-227
30. Verma S, Tuft SJ. Fusarium solani keratitis following LASIK for myopia. Br J Ophthalmol 2002;86:1190-1191
31. Espinel-Ingroff A, Boyle K, Sheehan DJ. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 2001;150:101-115
32. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003;41: 3623-3626
33. Pfaller MA, Messer SA, Hollis RJ, Jones RN, SENTRY Participants Group. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002;46:1032-1037
34. Rieger CT, Dittmer M, Ostermann H. [Liposomal amphotericin B in the treatment of severe fungal infections. Results of a clinical cohort trial]. Dtsch Med Wochenschr 2007;132: 2062-2066
35. Goldblum D, Frueh BE, Zimmerli S, Bohnke M. Treatment of postkeratitis fusarium endophthalmitis with amphotericin B lipid complex. Cornea 2000;19:853-856
36. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Ocular distribution of intravenously administered lipid formulations of amphotericin B in a rabbit model. Antimicrob Agents Chemother 2002;46:3719-3723
37. Goldblum D, Rohrer K, Frueh BE, Theurillat R, Thormann W, Zimmerli S. Corneal concentrations following systemic administration of amphotericin B and its lipid preparations in a rabbit model. Ophthalmic Res 2004;36:172-176
38. Pleyer U, Grammer J, Pleyer JH, Kosmidis P, Friess D, Schmidt KH, et al. [Amphotericin B-bioavailability in the cornea. Studies with local administration of liposome incorporated amphotericin B]. Ophthalmologe 1995;92:469-475
39. Morand K, Bartoletti AC, Bochot A, Barratt G, Brandely ML, Chast F. Liposomal amphotericin B eye drops to treat fungal keratitis: Physico-chemical and formulation stability. Int J Pharm 2007;344:150-153
40. Sponsel WE, Graybill JR, Nevarez HL, Dang D. Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis. Br J Ophthalmol 2002;86:829-830